.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,138,419

« Back to Dashboard

Details for Patent: 7,138,419

Title:Process for manufacturing bulk solutions and a lyophilized pure .alpha.-aztreonam lysinate
Abstract: A process for manufacturing bulk solutions and lyophilized pure .alpha.-aztreonam lysinate for large scale production of an inhalable aztreonam is disclosed, as is a pure .alpha.-aztreonam lysinate for inhalation. A dry powder or lyophilized pure .alpha.-aztreonam lysinate composition for inhalation is also disclosed.
Inventor(s): Montgomery; Alan Bruce (Medina, WA), Duncan; Iain (Seattle, WA), Carbonaro; Peter (Sammanish, WA)
Assignee: Corus Pharma, Inc. (Seattle, WA)
Filing Date:Jun 30, 2004
Application Number:10/882,985
Claims:1. A process for manufacturing a bulk solution of a pure .alpha.-aztreonam lysinate soluble in water or aqueous solvents having an impurity level 1% or lower, said pure .alpha.-aztreonam lysinate being suitable for aerosolization and delivery by inhalation, said process comprising steps: (a) preparing separately a solution of: (i) .alpha.-aztreonam dissolved in water or an aqueous solvent at acidic pH lower than pH 6.0 to form a slurry; and (ii) lysine monohydrate dissolved in water or an aqueous solvent; wherein both .alpha.-aztreonam and lysine are present in equimolar amounts in a ratio of 1.4:1.0 of .alpha.-aztreonam to lysine monohydrate; (b) reacting said .alpha.-aztreonam with said lysine to produce .alpha.-aztreonam lysinate without need for conversion of .alpha.-aztreonam to .beta.-aztreonam, wherein during said reaction said lysine solution is added to said .alpha.-aztreonam slurry or said .alpha.-aztreonam slurry is added to the lysine solution, and wherein said pure .alpha.-aztreonam lysinate has stability for about two years, wherein the level of impurities is 1% or lower.

2. The process of claim 1 additionally comprising step (c), purifying said .alpha.-aztreonam lysinate bulk solution until the level of impurities is 0.1% or lower.

3. The process of claim 1 additionally comprising step (d) lyophilizing the solution of step (b) into a lyophilizate having a water content between 0.3 and 0.5%.

4. The process of claim 1 wherein said step (b) is performed under continuous stirring and at a pH maintained between a value of 4.0 and 6.0.

5. The process of claim 1, further comprising purification of pure .alpha.-aztreonam lysinate bulk solution with charcoal or filtration, until the level of impurities is 0.1% or lower.

6. The process of claim 1 wherein said .alpha.-aztreonam lysinate bulk solution is vacuum or freeze dried.

7. The process of claim 1 wherein said .alpha.-aztreonam lysinate bulk solution comprises about 75 mg of .alpha.-aztreonam and about 52.5 mg of lysine monohydrate per one milliliter of water or aqueous solvent.

8. The process of claim 1 wherein said .alpha.-aztreonam lysinate bulk solution is freeze dried and has an impurity level lower than 1%.

9. The process of claim 1 wherein said pure .alpha.-aztreonam lysinate is substantially free of ethyl ester contaminant and ethyl alcohol residue.

10. The process of claim 1 wherein said .alpha.-aztreonam is combined and reacted with said lysine monohydrate is a lyophilizer.

11. The process of claim 1 wherein said .alpha.-aztreonam lysinate bult solution is spray-dried into a bulk solid .alpha.-aztreonam lysate.

12. A pure .alpha.-aztreonam lysinate suitable for inhalation treatment of pulmonary infections caused by gram-negative bacteria, wherein said pure .alpha.-aztreonam lysinate has levels of contaminants 1% or lower. wherein said pure .alpha.-aztreonam lysinate has stability, at said purity level 1% or lower, for about two years, wherein said .alpha.-aztreonam lysinate is dissolved in water or in an aqueous solvent into an aerosolable solution comprising 75 mg of .alpha.-aztreonam per one milliliter of the solvent, and having PH between 4.0 and 6.0, saline content from about 0.1 to about 0.90% of chloride and osmolality of from about 400 to about 550 mOsm/kg, and wherein said aerosolable solution is nebulized into an aerosol having a particle size with a mass medium average diameter from about 1 to about 5.mu. and delivered to a subject in need of said treatment.

13. The .alpha.-aztreonam lysinate of claim 12 wherein said .alpha.-aztreonam lysinate solution is lyophilized.

14. The .alpha.-aztreonam lysinate of claim 13 dissolved in from about 1 to about 5 mL of an aerosolable solution containing from about 0.1 to about 0.45% of chloride or an equivalent thereof.

15. The .alpha.-aztreonam lysinate of claim 12 lyophilized, freeze dried or vacuum dried into an inhalable dry powder and administered as the dry inhalable powder, wherein said dry powder has particle sizes predominantly between about 1 and about 5 microns and wherein said dry powder is delivered by a dry powder inhaler or by a metered dose inhaler.

16. An inhalable pharmaceutically acceptable composition comprising about 75 mg of pure .alpha.-aztreonam lysinate per one milliliter dose, said composition suitable for inhalable treatment of pulmonary bacterial infections caused by gram-negative bacteria, wherein said pure .alpha.-aztreonam lysinate has levels of contaminants 1% or lower, wherein said pure .alpha.-aztreonam lysinate has stability, at said purity level of 1% or, for about two years, wherein said .alpha.-aztreonam lysinate is dissolved in water or in an aqueous solvent into an aerosolable solution comprising 75 mg of .alpha.-aztreonam per one milliliter of the solvent, having pH between 4.0 and 6.0, saline content from about 0.1 to about 0.45% of chloride and osmolality of from about 400 to about 550 mOsm/kg, and wherein said aerosolable solution is nebulized into an aerosol having a particle size with a mass medium average diameter from about 1 to about 5 .mu. and is delivered to a subject in need of said treatment.

17. The composition of claim 16 wherein the .alpha.-aztreonam lysinate is spray dried into a powder having a particle size with a mass medium average diameter from about 1 to about 5.mu..

18. The .alpha.-aztreonam lysinate of claim 15 wherein the .alpha.-aztreonam lysinate dry powder has total impurities of about 0.84% after 6 months of storage at 50.degree. C.

19. The .alpha.-aztreonam lysinate of claim 15 having stability for at least two years wherein total impurities present in said .alpha.-aztreonam lysinate at two years are 1% or lower.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc